NRC Health
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRC research report →
Range $27 – $27
Price Chart
About the company
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning.
- CEO
- Trent Green
- IPO
- 2013
- Employees
- 357
- HQ
- Lincoln, NE, US
Get TickerSpark's AI analysis on NRC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $533.93M
- P/E
- 83.17
- Fwd P/E
- 18.36
- PEG
- -1.44
- P/S
- 3.71
- P/B
- -59.92
- EV/EBITDA
- 25.85
- Div Yield
- 2.54%
- Gross Margin
- 47.87%
- Op Margin
- 11.06%
- Net Margin
- 4.48%
- ROE
- 103.40%
- ROIC
- 9.54%
Latest fiscal year · YoY change
- Revenue
- $137.39M-4.0%
- Gross Profit
- $77.39M-10.1%
- Op Income
- $22.59M
- Net Income
- $11.60M-53.2%
- EPS
- $0.52-50.5%
- OCF Growth
- -23.6%
- FCF Growth
- -17.9%
- 52W High
- $27.60
- 52W Low
- $11.73
- 50D MA
- $22.58
- 200D MA
- $19.60
- Beta
- 0.38
- RSI (14)
- 55
- Avg Volume
- 110.81K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
NRC Health posted double-digit TRCV growth, modest revenue growth, and steady margins while investing in delivery capacity and new product capabilities ahead of future revenue conversion.· October 27, 2026
- TRCV reached $151.9 million, up 11% year over year, with strength in Experience, Market Insights, and the Governance Institute.
- Q2 revenue rose about 4% year over year and 2% sequentially, though about 2 points of growth were offset by a revenue recognition change in reputation management SKUs.
- Adjusted EBITDA margin was 27% and adjusted EBITDA was $9.4 million; management said margins should improve later in the year as revenue catches up to booked TRCV.
- The Landmark multi-solution win is now live, with the first 25 hospitals and some ambulatory sites onboarded and revenue starting to be recognized in July.
- Pipeline activity remained strong, with pipeline up 60% year over year and sales activity up 35%, though average deal size was down due to market uncertainty after the Qualtrics/Press Ganey combination.
Q2 2026 TRCV was $151.9 million, up 11% year over year. Revenue increased approximately 4% year over year and 2% sequentially, including about a 2-point headwind from a revenue recognition change tied to certain reputation management SKUs. Adjusted EBITDA was $9.4 million with a 27% margin, and adjusted EPS was $0.31 per diluted share; adjusted net income was $6.9 million. Q2 free cash flow was $0.062 million, up $4.2 million from the prior year. For the next quarter, management expects Q3 revenue to increase sequentially and adjusted EBITDA margin to be approximately the same as the first half of the year, with fourth-quarter EBITDA margin upside as revenue scales and expenses normalize. They also expect the Q2 gross-to-net revenue headwind to be smaller in Q3 and Q4, and the effective tax rate to be approximately 4.0% in both Q3 and Q4.
Trent Green framed the quarter as another strong execution period, highlighting 11% TRCV growth, diversified bookings, and progress in both the Governance Institute and AI-enabled experience tools. He emphasized NRC Health’s strategy of combining healthcare-specific data, governance expertise, and workflow enablement to turn insight into action. His tone was confident and upbeat, but disciplined: he repeatedly said the company is investing deliberately now to support future growth and margin expansion later in the year.
Shane Harrison focused on the mechanics behind the quarter: TRCV of $151.9 million, revenue up about 4%, adjusted EBITDA of $9.4 million at a 27% margin, adjusted EPS of $0.31, and free cash flow of $0.062 million. He explained that a roughly 2-point revenue headwind came from a gross-to-net accounting change on several reputation management SKUs, while also noting that the underlying TRCV-to-revenue conversion should support durable growth as implementations ramp. On capital allocation, he said NRC paid its regular quarterly dividend of $0.16 per share, repurchased about 397 thousand shares, and will keep balancing internal investment, possible M&A, and opportunistic buybacks with a prudent leverage profile.
Analysts focused on the Governance Institute, the Landmark win, AI monetization, and the competitive impact of Qualtrics/Press Ganey. Management said the Governance Institute is about 10% of the business, has strong margins, and will not be a major near-term top-line driver, though it is strategically important for cross-sell and executive access. On Landmark, NRC said the first 25 hospitals and some ambulatory sites are live, revenue recognition began this month, and the deal includes another rounding product expected to kick off in the second half of 2027. On competition, Trent said the market is in a period of buyer uncertainty after the acquisition, with some RFPs pausing and reassessing; he also said customers do not yet have clarity on the combined platform’s migration plans.
The call pointed to broad-based momentum: double-digit TRCV growth, a 60% increase in pipeline, and a live Landmark deployment that should contribute more revenue as additional facilities come online. Management also sounded confident that NRC’s healthcare-specific data, governance relationships, and embedded workflow tools create a differentiated moat, especially as AI and cross-sell opportunities expand.
Near-term revenue is still being held back by timing, including the gross-to-net accounting change and the ramp of large implementations, while EBITDA margins are being held flat as the company invests ahead of growth. Management also flagged that average deal size is down and that some customers are pausing RFPs because of uncertainty around the Qualtrics/Press Ganey combination, which could keep buying decisions choppy in the near term.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 52.1%
- Shares Outstanding
- 21.22M
- Float Shares
- 11.06M
of shares held by institutions
124 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kayne Anderson Rudnick Investment Management LLC | 1.83M | ▼ 198.59K |
| Blackrock, Inc. | 1.05M | ▼ 7.13K |
| Morgan Stanley | 855.75K | ▼ 3.52K |
| Vanguard Group Inc | 831.38K | ▼ 90.03K |
| Vanguard Capital Management LLC | 652.32K | ▼ 14.24K |
| Farmers & Merchants Investments Inc | 501.73K | ▲ 171.08K |
| Dimensional Fund Advisors LP | 491.67K | ▲ 438 |
| Willis Investment Counsel | 430.99K | ▼ 3.80K |
| Geode Capital Management, LLC | 411.57K | ▼ 8.49K |
| Qv Investors Inc. | 372.50K | 0 |
| Renaissance Technologies LLC | 313.58K | ▼ 11.80K |
| Heartland Advisors Inc | 300.00K | 0 |
Held by 172 ETFs
Biggest fund positions in NRC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Hrdy Helen | other | 12,619 |
| Nov 10, 26 | Hrdy Helen | other | 10,491 |
| Nov 10, 26 | Hrdy Helen | other | 12,619 |
| Jun 23, 26 | Berwick Donald M | other | 7,697 |
| Jun 23, 26 | Bhandari Parul | other | 7,697 |
| Jun 23, 26 | Lockhart Stephen H | other | 7,697 |
| Jun 23, 26 | NUNNELLY JOHN N | other | 7,697 |
| Jun 23, 26 | Wheeler Penny Ann | other | 7,697 |
| Mar 12, 26 | Rau Jason Russell | other | 60,000 |
| Feb 17, 26 | HARRISON SHANE R | buy | 8,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRC coverage
Recent articles, reports, and earnings notes.
No research on NRC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRC report →Nuclear Stocks Could Deliver BAAJA Bounces
etftrends.com · Nov 19
NRC Issues Permit for Reactors Powering Chemical Plant
etftrends.com · Nov 16
RecycLiCo receives funding from the National Research Council of Canada to collaborate on advancing AI-driven optimization of a hydrometallurgical platform for critical minerals recovery
globenewswire.com · Nov 16
NRC Health: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 8
Terra Innovatum Achieves Key NRC Licensing Milestone, Delivers All 18 SOLO™ PSAR Chapters for Readiness Review as it Advances Toward 2027 First Reactor Deployment
globenewswire.com · Nov 4
NRC Completes Landmark Safety Review of X-energy's Xe-100 SMR
globenewswire.com · Oct 30
RETRANSMISSION: Manganese X Energy Provides Battery Hill High-Purity Manganese Sample for NRC-Led POSCO LMR Cathode Research Project
newsfilecorp.com · Oct 30
Manganese X Energy Provides Battery Hill High-Purity Manganese Sample for NRC-Led POSCO LMR Cathode Research Project
newsfilecorp.com · Oct 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.